Search for AL amyloidosis risk factors using Mendelian randomization.
Autor: | Saunders CN; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom., Chattopadhyay S; Department of Clinical Genetics, Lund University, Lund, Sweden., Huhn S; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany., Weinhold N; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany., Hoffmann P; Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany.; Department of Biomedicine, University of Basel, Basel, Switzerland., Nöthen MM; Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany., Jöckel KH; Institute for Medical Informatics, Biometry, and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Schmidt B; Institute for Medical Informatics, Biometry, and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Landi S; Department of Biology, University of Pisa, Pisa, Italy., Goldschmidt H; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.; National Centre of Tumor Diseases, Heidelberg, Germany., Milani P; Amyloidosis Research and Treatment Center, Foundation 'Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo' and Department of Molecular Medicine, University of Pavia, Pavia, Italy., Merlini G; Amyloidosis Research and Treatment Center, Foundation 'Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo' and Department of Molecular Medicine, University of Pavia, Pavia, Italy., Rowcieno D; National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, United Kingdom., Hawkins P; National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, United Kingdom., Hegenbart U; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany., Palladini G; Amyloidosis Research and Treatment Center, Foundation 'Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo' and Department of Molecular Medicine, University of Pavia, Pavia, Italy., Wechalekar A; National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, United Kingdom., Schönland SO; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany., Försti A; Hopp Children's Cancer Center, Heidelberg, Germany.; Division of Pediatric Neuro-oncology, German Cancer Research Center, German Cancer Consortium, Heidelberg, Germany., Houlston R; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom., Hemminki K; Biomedical Center, Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, Pilsen, Czech Republic; and.; Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany. |
---|---|
Jazyk: | angličtina |
Zdroj: | Blood advances [Blood Adv] 2021 Jul 13; Vol. 5 (13), pp. 2725-2731. |
DOI: | 10.1182/bloodadvances.2021004423 |
Abstrakt: | In amyloid light chain (AL) amyloidosis, amyloid fibrils derived from immunoglobulin light chain are deposited in many organs, interfering with their function. The etiology of AL amyloidosis is poorly understood. Summary data from genome-wide association studies (GWASs) of multiple phenotypes can be exploited by Mendelian randomization (MR) methodology to search for factors influencing AL amyloidosis risk. We performed a 2-sample MR analyzing 72 phenotypes, proxied by 3461 genetic variants, and summary genetic data from a GWAS of 1129 AL amyloidosis cases and 7589 controls. Associations with a Bonferroni-defined significance level were observed for genetically predicted increased monocyte counts (P = 3.8 × 10-4) and the tumor necrosis factor receptor superfamily member 17 (TNFRSF17) gene (P = 3.4 × 10-5). Two other associations with the TNFRSF (members 6 and 19L) reached a nominal significance level. The association between genetically predicted decreased fibrinogen levels may be related to roles of fibrinogen other than blood clotting. be related to its nonhemostatic role. It is plausible that a causal relationship with monocyte concentration could be explained by selection of a light chain-producing clone during progression of monoclonal gammopathy of unknown significance toward AL amyloidosis. Because TNFRSF proteins have key functions in lymphocyte biology, it is entirely plausible that they offer a potential link to AL amyloidosis pathophysiology. Our study provides insight into AL amyloidosis etiology, suggesting high circulating levels of monocytes and TNFRSF proteins as risk factors. (© 2021 by The American Society of Hematology.) |
Databáze: | MEDLINE |
Externí odkaz: |